ImageneBio, Inc. (IMA): who owns it and who trades it
As of Nov 16, 2026, IMA insiders reported 2 open-market sales worth $17.3K and 1 purchase worth $95.8K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert B Lally (Principal Accounting Off), with $17.3K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling ImageneBio
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IMA
35 funds and institutions reported IMA shares worth $36.8M at the end of Q2 2026, about 55% of the company. The largest holder is Bvf Inc with 9.8%.
Funds and institutions (13F) 55%Everyone else 45%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Bvf Inc | 1.11M | 9.84% | $6.5M | No change |
| Blue Owl Capital Holdings LP | 917,692 | 8.14% | $5.4M | -4% |
| Orbimed Advisors LLC | 909,269 | 8.06% | $5.4M | +140% |
| Cable Car Capital, LP | 781,599 | 6.93% | $4.6M | +4% |
| Omega Fund Management, LLC | 455,361 | 4.04% | $2.7M | No change |
| Rtw Investments, LP | 334,445 | 2.97% | $2M | No change |
| Vanguard Capital Management LLC | 320,518 | 2.84% | $1.9M | -1% |
| Trails Edge Capital Partners, LP | 282,004 | 2.50% | $1.7M | New |
| BML Capital Management, LLC | 200,730 | 1.78% | $1.2M | No change |
| Monashee Investment Management LLC | 192,344 | 1.71% | $1.1M | New |
| BlackRock, Inc. | 135,090 | 1.20% | $797K | +5% |
| Renaissance Technologies LLC | 86,930 | 0.77% | $513K | +6% |
| Adage Capital Partners Gp, L.l.c. | 66,666 | 0.59% | $393K | No change |
| Citadel Advisors LLC | 55,610 | 0.49% | $328K | -55% |
| Geode Capital Management, LLC | 53,512 | 0.47% | $316K | -11% |
| NEA Management Company, LLC | 50,005 | 0.44% | $295K | No change |
| Nano Cap New Millennium Growth Fund L P | 50,000 | 0.44% | $295K | +67% |
| HSBC Holdings PLC | 34,228 | 0.30% | $208K | -2% |
| Sofinnova Investments, Inc. | 31,884 | 0.28% | $188K | No change |
| Vanguard Fiduciary Trust Co | 27,475 | 0.24% | $162K | +1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IMA insiders reported $95.8K of open-market purchases and $17.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | Robert B Lally | Principal Accounting Off | Sale | 1,525 | $5.34 | $8.1K | Form 4 |
| Jul 16, 2026 | Robert B Lally | Principal Accounting Off | Sale | 1,671 | $5.50 | $9.2K | Form 4 |
| Dec 24, 2025 | Joseph P Slattery | Director | Purchase | 16,000 | $5.99 | $95.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Joseph P Slattery | Director | $95.8K | – | Dec 24, 2025 |
| Robert B Lally | Principal Accounting Officer | – | $17.3K | Jul 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMA short interest
Low short interest. 0.4% of IMA shares are sold short: about 1 share in 247. Over the last 12 reports the number of shares short went down 90%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 45,958 IMA shares were sold short, 0.4% of the shares outstanding, down 25.1% from the report before. At the average daily volume of 11,613 shares, buying them all back would take about 4.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 45,958 | 0.40% | -25% | 11,613 | 4.0 |
| Oct 15, 2026 | 61,349 | 0.54% | +87% | 14,638 | 4.2 |
| Sep 30, 2026 | 32,852 | 0.29% | -5% | 17,299 | 1.9 |
| Sep 15, 2026 | 34,601 | 0.30% | -12% | 15,047 | 2.3 |
| Aug 31, 2026 | 39,412 | 0.35% | -20% | 11,704 | 3.4 |
| Aug 14, 2026 | 49,297 | 0.43% | -87% | 9,956 | 5.0 |
| Jul 31, 2026 | 384,525 | 3.39% | -2% | 12,991 | 29.6 |
| Jul 15, 2026 | 393,691 | 3.49% | -3% | 6,664 | 59.1 |
| Jun 30, 2026 | 404,370 | 3.59% | +2% | 12,826 | 31.5 |
| Jun 15, 2026 | 395,934 | 3.51% | -11% | 16,416 | 24.1 |
| May 29, 2026 | 445,327 | 3.95% | +0% | 15,677 | 28.4 |
| May 15, 2026 | 445,009 | 3.95% | -5% | 69,314 | 6.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
ImageneBio company events
ImageneBio filed 12 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 23, 2026LeadershipImageneBio, Inc., a Delaware corporation, based in part on the recommendation of Kristin Yarema, Ph.D., the Company’s Chief Executive Officer, appointed Yanina Grant-Huerta as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective July 20, 2026. Filing
- Jun 26, 2026LeadershipRobert Lally, our Senior Vice President of Finance and Operations and principal accounting officer, provided notice of his resignation, effective July 22, 2026. Filing
- Jun 17, 2026LeadershipImageneBio, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 13, 2026AgreementImageneBio, Inc., a Delaware corporation, entered into a Securities Purchase Agreement with certain institutional and accredited investors, pursuant to which the Company agreed to sell and issue pre-funded warrants to purchase shares of the Company’s voting common stock, par value $0.001 (“Common… Filing
- Mar 17, 2026LeadershipImageneBio, Inc. and Erin Butler, the Company’s Senior Vice President, Finance & Administration and Principal Accounting Officer, agreed to a mutual separation effective March 20, 2026. Filing
- Mar 10, 2026ResultsReleased financial results. Filing
- Feb 17, 2026LeadershipSteven Hui Wang resigned as a member of the Board of Directors of ImageneBio, Inc., effective immediately. Filing
- Dec 18, 2025LeadershipYufang Lu, M.D., Ph.D., our Chief Medical Officer, provided notice of her resignation, effective December 31, 2025. Filing
- Nov 19, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
ImageneBio financials
Famous investors that hold IMA
2 of the 50 well-known investors we track reported holding IMA in their latest 13F filing. The largest position is Jim Simons's, worth $360K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 78,495 | $360K | 0.0% | -10% |
| Israel Englander · Millennium Management | Q3 2026 | 40,386 | $185K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IMA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Blue Owl Capital Holdings LP | 13G/A | 9.1% |
| Nov 13, 2026 | Blue Owl Capital Holdings LP | 13G/A | 9.1% |
Questions about ImageneBio, Inc. (IMA) stock
Who owns the most IMA stock?
The largest reported owner of ImageneBio, Inc. (IMA) is Bvf Inc, with 9.8% of the company. In total, 35 funds and institutions reported holding IMA at the end of Q2 2026, together about 55% of the shares. See the largest owners.
Are IMA insiders buying or selling?
In the last 12 months, IMA insiders reported 1 open-market purchase worth $95.8K and 2 sales worth $17.3K. The latest trade was on Jul 17, 2026. See every trade.
What is the short interest in IMA?
As of Oct 30, 2026, 45,958 IMA shares were sold short, 0.4% of the shares outstanding, down 25.1% from the report before. At the average daily volume of 11,613 shares, buying them all back would take about 4.0 trading days (days to cover). See the history.
Which famous investors hold IMA?
2 of the 50 well-known investors we track reported IMA in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $360K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.